By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications may not be sufficient in helping them reach their target cholesterol levels.

People who have tried medication to lower their dangerously high levels of cholesterol and other blood fats – without success ...

Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...

Older adults face unique barriers in hypertension management, including comorbidities, mobility limitations, and medication adherence challenges, impacting digital health tool effectiveness. Trials ...

Dangerously high levels of “bad” cholesterol and triglycerides may be reduced by gene editing, in what study researchers hope will be a “one and done” treatment.

An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers ...

High cholesterol is a major driver of heart disease. Statins, like Lipitor and Zocor, emerged as powerful antidotes starting ...

Federal and state health officials are investigating 13 cases in 10 U.S. states of infant botulism linked to baby formula ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...